Security key
35104E100
4D Molecular Therapeutics, Inc. - Common Stock, $0.0001 par value per share (FDMT)
CUSIP: 35104E100
Q1 2025 13F Holders as of 31 Mar 2025
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Total 13F shares
- 43,058,381
- Total 13F value
- $139,823,044
- Share change
- -3,715,831
- Put/Call ratio
- 128%
- SEC-reported price per share
- $3.23
- Number of holders
- 122
- Value change
- -$22,403,324
- Number of buys
- 47
- Number of sells
- 93
- Shares outstanding
- 51,571,939
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2025
Institutions
122
Top holders
10
FDMT full security history
Ownership snapshot
Full 13F holder table
4D Molecular Therapeutics, Inc. SEC filings
4D Molecular Therapeutics, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of FDMT - 4D Molecular Therapeutics, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Venrock Healthcare Capita...
Disclosed value leader
RA CAPITAL MANAGEMENT, L.P.
Comparable rows
15/15
Latest evidence
31 Mar 2025
13D/G
13F
3/4/5
Lead comparable stake: 1.5%
13D/G row: Venrock Healthcare Capital Partners III, L.P.
Showing 1-6 of 15 holder rows.
Quick read
Venrock Healthcare Capital Partners III, L.P. leads the comparable SEC ownership view at 1.5%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Venrock Healthcare Capital Partners III, L.P.'s linked filing trail.
Comparable ownership
Top 5
Venrock Healthcare Capital Partne...
1.5%
Deep Track Capital, LP
1.3%
BlackRock, Inc.
9.5%
RA CAPITAL MANAGEMENT, L.P.
8.8%
GOLDMAN SACHS GROUP INC
8.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
1.5%
|
$2,202,200
677,600 shares
|
-$7,393,006 | 31 Mar 2025 |
| Deep Track Capital, LP |
13F
13D/G
Company
|
1.3%
from 13D/G
|
$3,397,143
609,900 shares
|
— | 31 Dec 2024 |
| BlackRock, Inc. |
13F
Company
|
9.5%
|
$27,411,760
4,921,321 shares
|
— | 31 Dec 2024 |
| RA CAPITAL MANAGEMENT, L.P. |
3/4/5
13F
10%+ Owner · Company
|
8.8%
from 13F
|
$74,517,236
8,173,211 shares
mixed-class rows
|
— | 09 Dec 2024 |
| GOLDMAN SACHS GROUP INC |
13F
Company
|
8.3%
|
$23,811,600
4,274,973 shares
|
— | 31 Dec 2024 |
| Venrock Adviser, LLC |
13F
Company
|
5.7%
|
$16,444,706
2,952,371 shares
|
— | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
122
Shares
43,058,381
Rows available
122
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2025 vs Q1 2025 Across Filers
Q1 2025 holders
122
Q1 2025 holders
122
Holder diff
0
| Investor | Q1 2025 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q1 2025 value | Value change | Value Chg % |
|---|